Loading organizations...
§ Private Profile · College Park, GA, USA
Clinical-stage biopharmaceutical company developing broad-spectrum antiviral medications for RNA viral pathogens and high-risk patients.
Founded in 2021 by George Painter, Dennis Liotta, John Clerici, and Seth Rudnick, Altesa BioSciences is a clinical stage biopharmaceutical company based in College Park, Georgia. The enterprise develops broad spectrum oral antiviral therapeutics targeting RNA viral pathogens, including rhinovirus, enterovirus, norovirus, and flaviviruses, to address unmet medical needs in high income countries. To build its clinical pipeline, the organization licenses compounds from academic and corporate partners, notably acquiring exclusive global rights to the clinical stage antiviral vapendavir from Vaxart. Additionally, the business is advancing ALT-2023 as the first of six molecules licensed from Emory University, while currently seeking $50 million in Series A funding for Phase 2 trials. The executive leadership team includes former FDA Acting Commissioner Brett Giroir as Chief Executive Officer and former Operation Warp Speed chief advisor Moncef Slaoui as Board Chair.
Altesa has raised $79.0M across 2 funding rounds.
Altesa has raised $79.0M in total across 2 funding rounds.
Altesa has raised $79.0M across 2 funding rounds. Most recently, it raised $75.0M Series B in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 19, 2026 | $75M Series B | JON Edwards | Atlantic Partners, Medicxi, Pitango Venture Capital, Sanofi | Announced |
| Feb 10, 2022 | $4M Seed | Pitango Venture Capital | GRA Venture Fund | Announced |
Altesa has raised $79.0M in total across 2 funding rounds.
Altesa's investors include Jon Edwards, Atlantic Partners, Medicxi, Pitango Venture Capital, Sanofi, GRA Venture Fund.